Cardiff Oncology Q1 2024 GAAP EPS $(0.22) Beats $(0.25) Estimate, Sales $205.000K Beat $55.000K Estimate
Cardiff Oncology Q1 2024 GAAP EPS $(0.22) Beats $(0.25) Estimate, Sales $205.000K Beat $55.000K Estimate
加的夫腫瘤學2024年第一季度GAAP每股收益美元（0.22美元）超過預期（0.25美元），銷售額20.5萬美元超過預期的5.5萬美元
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.25) by 12 percent. This is a 12 percent increase over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $205.000 thousand which beat the analyst consensus estimate of $55.000 thousand by 272.73 percent. This is a 146.99 percent increase over sales of $83.000 thousand the same period last year.
加的夫腫瘤學（納斯達克股票代碼：CRDF）公佈的季度虧損爲每股0.22美元，比分析師普遍預期的0.25美元（0.25美元）高出12％。這比去年同期每股虧損0.25美元（0.25美元）增長了12％。該公司公佈的季度銷售額爲20.5萬美元，比分析師普遍預期的55,000美元高出272.73％。這比去年同期的83,000美元銷售額增長了146.99％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。